This article discusses a study on the use of risankizumab for the treatment of genital psoriasis. Genital involvement in psoriasis can have a significant impact on quality of life and sexual activity. The study found that risankizumab, a monoclonal antibody that blocks interleukin-23, was effective in reducing psoriasis symptoms in the genital area. The treatment showed a fast onset of action and sustained effectiveness for up to 52 weeks. The study also reported a favorable safety profile, with no relevant adverse events or treatment discontinuation due to side effects. However, further research is needed to evaluate long-term management of genital psoriasis. [Extracted from the article]